Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TLR2 | O60603 | 13/20 | 0.33 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906341 | 1.00 | MEN1 (0.39) | MEN1KMT2ATLR2SUCNR1GAA | |
| SCHEMBL22398650 | 0.84 | MEN1 (0.47) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL22398651 | 0.84 | MEN1 (0.47) | MEN1KMT2ATLR2CA2 | |
| SCHEMBL22687577 | 0.82 | MEN1 (0.43) | MEN1KMT2ATLR2SUCNR1CA2 | |
| SCHEMBL18906990 | 0.81 | GNAI3 (0.48) | MEN1KMT2ATLR2GAACA2 | |
| SCHEMBL18906904 | 0.81 | GNAI3 (0.48) | MEN1KMT2ATLR2GAACA2 | |
| SCHEMBL18906998 | 0.81 | GNAI3 (0.37) | TLR2CA2CA1 | |
| SCHEMBL21018608 | 0.80 | CA1 (0.42) | MEN1KMT2AGAACA2CA1 | |
| SCHEMBL20158288 | 0.79 | CA2 (0.40) | MEN1KMT2AGAACA12CA2 | |
| SCHEMBL17337882 | 0.78 | CA2 (0.55) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-16 | — | — | US | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2020-09-24 | — | — | US | disclosed |
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2019-05-23 | — | — | US | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | MEN1 4102/4885KMT2A 1593/4885TLR2 1883/4885 |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | MEN1 2448/4885KMT2A 1130/4885TLR2 2201/4885 |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | PA2G4, FCGRT, CLTB | MEN1 4102/4885KMT2A 1593/4885TLR2 1883/4885 |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LPO, NOXO1, DAO | MEN1 3070/4885KMT2A 1610/4885TLR2 2947/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | MEN1 4102/4885KMT2A 1593/4885TLR2 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.